healthcare medical

government public service

e-commerce shopping

documentation technical

corporate business

English

_ga_K065KBPWHF

_fbp

Within the commercial generic top-level domain (.com), 'www.livenowlongevity.com' is registered with subdomain 'www'. The second-level label 'livenowlongevity' is 16 characters long containing 6 vowels alongside 10 consonants. Breaking it apart gives 3 words: live, now, longevity. Median word length is 4 characters. No strong language cues emerged from the frequency lists.

html/85/83/85832172-ab56-4992-a67a-c68777e99106.html.gz

inline; filename="e8f2fbee2754df70-s.p.0fzkl03jw-sdz.woff2"

inline; filename="turbopack-0xrng-vt.nz0_.js"

inline; filename="cf514f5d0007dafa-s.0lok5zj4ubzox.woff2"

inline; filename="dr-charles-kamen-portrait.jpg"

317b6e438c77d4bfd1e1d9143827405545e7753c7ea3cb8027bd01328b5da3e0

c237dd28b6d9313fb753dc08992cfaef263dd594d55a302587cee04ceffb5776

802dd65070a69cffd24df7fdc1f451b9f896dfc5575846f2f520612f6d5857f1

5261101892e2476e4346e19e86fd5f19cbcf7c765ff76e92eb9cefcc86b6db6a

0821a01fa5189a7f7f8d1cf1d3ab8e87e31e8196f2046b3639ad7dd440af7bea

7ee6b90db9e058a0a36a0eb62dac3c7cf6ab498b0399e226c4c86b48e95c9107

9db39118d356154bdc60d35be9d552ca2e99ad8dd70a0f9e446feb84a16987d8

26bb05ecbd06e5977d4d2f279de4e9b82866f13306d1ef4059569edb0cbef280

a3ac200f3ab8bfa57cf78882057741ddb5c0fbc9e2490c5d951c099b37484206

4808740d98dca5f8698e3c1d05e6989180a608fcf212f686c43b6cb67339a8f0

830c5271e22750775d09ed4f16f52ec63a02bf189f77984101f2c4c666164a00

4a61c459147af66803aaa44a257c1c76b3ca25c10f500c1241ea8286709b4716

587897b5cb7ab859d148d74d786a957ee9eeb43c740df3da47453bba9efc075b

2f6afb4ae620c9e06de10109baa449a774cfa0c4036de3b470aac7a0bfe3bd51

b3fd51782449d0c834affc59c11e17dc030c50eb30870fc6fd046757e9b701ec

eb036430a1df109f65576f4cd1c47c3f8a6600879283e05fc54a595466d5f210

894d9d866a74f1057a3ef513c354cab27cc744cce90b961594e78b16ae0a29c4

90840c594768159dcf6b0d672978a94c22e1b165fa21bc411987e0e3e8e09fe7

19ccaffc1bf72a53b82e3cdb6c3709dfffa121af61806cf6f5bf0506e30d7f3d

743f634afb680936ec0b93706b03dff43a48b467041c6188f6bd0678d3005b8e

bda83d88e4e1b2c00bc55f47b182b9a1c6e70b6714c54ddda4fddf939c06dcb9

default-src *.facebook.com *.fbcdn.net *.facebook.net 'self' blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net blob: 'self' 'nonce-wfRxVeGW';style-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob: 'unsafe-inline';connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net wss://*.facebook.com:* wss://*.fbcdn.net attachment.fbsbx.com *.cdninstagram.com blob: 'self' data: https://edge-chat.facebook.net https://edge-chat-latest.facebook.net wss://edge-chat-latest.facebook.net wss://edge-chat.facebook.net wss://edge-chat.socialplugin.facebook.net wss://edge-chat-latest.socialplugin.facebook.net https://edge-chat.socialplugin.facebook.net https://edge-chat-latest.socialplugin.facebook.net;font-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;img-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;media-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;child-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;frame-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;manifest-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;object-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;worker-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;block-all-mixed-content;upgrade-insecure-requests;report-uri https://www.facebook.com/csp/reporting/?m=c&minimize=0;

46f16fb836dd65d539070455f5202fd4ef6e33245c14a7d8abcebb7f961c8fd8

default-src *.facebook.com *.fbcdn.net *.facebook.net 'self' blob:;script-src *.facebook.com *.fbcdn.net *.facebook.net blob: 'self' 'nonce-mLsm8xq1';style-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob: 'unsafe-inline';connect-src *.facebook.com facebook.com *.fbcdn.net *.facebook.net wss://*.facebook.com:* wss://*.fbcdn.net attachment.fbsbx.com *.cdninstagram.com blob: 'self' data: https://edge-chat.facebook.net https://edge-chat-latest.facebook.net wss://edge-chat-latest.facebook.net wss://edge-chat.facebook.net wss://edge-chat.socialplugin.facebook.net wss://edge-chat-latest.socialplugin.facebook.net https://edge-chat.socialplugin.facebook.net https://edge-chat-latest.socialplugin.facebook.net;font-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;img-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;media-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;child-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;frame-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;manifest-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;object-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;worker-src *.facebook.com *.fbcdn.net *.facebook.net 'self' data: blob:;block-all-mixed-content;upgrade-insecure-requests;report-uri https://www.facebook.com/csp/reporting/?m=c&minimize=0;

cf6a2e5b441a624ba64f9d95464ac8ad63e31f8ccb6982ad8052bcb37fd5402f

6e68e7d0e9e4fb256ee97c1e68898468d7882a9bfc338e1e1bab6f840b9b30e7

25782c80050731871e72cfe84b37340aba17fa423a2cade75342920fb76dc311

e851e1f4b5177c96a7f8f2ac835d376960ec06f9d8e5d080217013b5845585b0

a318fc494a007d7a2b8f136ab53c21f6c6f1758830e8263d127df5816b56c82f

3814cddd18b2095e01abb745a99e5ada90178e709c09879324c3b623f2d829ea

7da3d2876e8dbf974d096875488e88b71c71b3840ae878fb62f99ca2da83eeaf

0d5875c94821353b5dc5dd0e97107471fc2fe33fa652a42ada648aaf9b24dbb2

ddc90ab3635fd94fe0efe1e62884a04467c3eccf3d5e22c1afe04d515ace5acc

36baea40aaa8b14cd5e2e9217bbede7a591a649307423c3e5f73c5cff03af661

d7240112d8275934e8010125bc73c0c1175937ce7263fee8722cd73479770fa9

9d7ea302eafbf95478d40d93376f62c433c9aff3d3a75762d9a571d035e33842

af50384059d8bad27c0edeb7f0f1b8e18527d77dd1ed53bf2c0ad25a0e886d23

870ff099fe598cf73ac5e572fe7366ad172cde70c6921215f35a03411e90cf71

5ce5f00a8088511b9fe9518087f25713f5d87d49eaedc6b8e12e9d1f07a0b8a3

bd8538a666d661fdef0151a9389bd5fc4b96edc629a8d3a8e16ab857ad2627b8

64ab54bb32a6ce9ae1a48856711a522db4811b1005c6453a277960e3c3f9aa07

de496c288a556360adf8880b7a740006885645af9784cbe58e4dd3ff51b317df

ba807a5333f1b943ed4c6364aa16cd7f00c63dfb6c0f41c87987bc524149ff22

4d9c7de59bc9690f11f9e1cc1b1bc88bea0798140e12fb0ad13c845b2354d829

b0fc0319a6f205b4bcf209af8ec8f739315dec3f8584786c9ebfa9b228d4e29b

c51233c51c6ddc31de9295411e124ce00b2dc6862b6d114694954848ba65043d

b8e46a13df237c2fa7cd55090349a6cd835a6006f108a3ce9f804575453aec35

3db52819f68ed1cac42eec5788bbf92879f4082fcf3c929d71d3e40684e86b8e

0825d759757d91c57901276b18514d5a3b6942ef1c5dfc9e18c727f0d235db52

fd00ccd1c5ed660588596606e610b8dcfa1b1631215b887b100012ab597a1261

46cf200896812bcaefafdc6bd07524b6201a346693141135e7e9b25678e584dc

9280ae3b42f168ce276d02e352ef2a2437e225e323bb0aef37b349e628ec123d

9c2f83993a692cf3b900c0ec730611220ffda2206da8a5f23a0c817baccc2caf

479f8455b6005e346a9b8c3cda1ffcf1728234eeec4eb1ff8e494f8c9b9a7ffd

58f1f5cce4caca5cf0aaeb55c5f9d398067cda95f4910c2f1d1c728385b1dae7

5c6a9fb1ec88d7b475bf08a65ab9769c72d81d6aa082b7a2ca004368cb034b4b

8eaaa528e2fb7506c24bfa6c4992e1a49dffcfe264231c77dd3ca8d1e143e08d

a997a3b87d1ffb0c833453d4642b364040c217f6493948ec837d876160482440

Live
Now
Longevity
PHYSICIAN-GUIDED
·
LAS VEGAS

FDA — Pharmacy Compounding Advisory Committee; Notice of Meeting (July 23–24, 2026). Federal Registe

FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1 / 2 / 3 l

FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (program hub).

FDA — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposes N

FDA — Extension of Comment Period for the 503B clinical-need notice (comment period extended to July

FDA — Human Drug Compounding Laws (conditions for the 503A and 503B exemptions).

PHYSICIAN-LED PEPTIDE THERAPY IN LAS VEGAS. VISIT OUR CLINIC

viewport

geo.region

geo.placename

geo.position

ICBM

theme-color

mobile-web-app-capable

apple-mobile-web-app-capable

apple-mobile-web-app-status-bar-style

apple-mobile-web-app-title

next-size-adjust

A physician, primary-source tracker of where 25 peptides stand with the FDA — 503A categories, the July 2026 PCAC agenda, and the GLP-1 503B proposal.

description

author

peptide FDA status, is BPC-157 legal, 503A bulks list peptides, PCAC July 2026 peptides, FDA peptide compounding 2026, are peptides FDA approved, semaglutide 503B, TB-500 FDA, peptide regulatory tracker

keywords

referrer

creator

publisher

robots

googlebot

classification

og:locality

og:region

og:country-name

Content is for educational purposes only and is not medical advice.

medical:disclaimer

medical:reviewedBy

format-detection

hoRAnalqKKczOStSrnIul57E_D0zXvpuw6-h4k4OyPc

google-site-verification

facebook-domain-verification

Peptide Regulatory Status Tracker (2026) — FDA 503A, PCAC & GLP-1

Where 25 peptides stand with the FDA right now — 503A categories, the July 2026 PCAC agenda, and the GLP-1 503B proposal. Primary-source, physician-reviewed, free to reuse.

https://www.livenowlongevity.com/peptide-regulatory-tracker

https://www.livenowlongevity.com/api/og?title=Peptide%20Regulatory%20Status%20Tracker&description=FDA%20503A%2C%20the%20July%202026%20PCAC%20agenda%2C%20and%20GLP-1%20503B%20%E2%80%94%20Dr.%20Charles%20Kamen%2C%20MD.

Peptide Regulatory Status Tracker - LiveNow Longevity

twitter:card

twitter:site

twitter:creator

Peptide Clinic in Las Vegas | Physician-Led Peptide Therapy — LiveNow Longevity

twitter:title

Physician-supervised peptide therapy, weight management, NAD+ IV therapy, and regenerative medicine in Las Vegas.

twitter:description

https://www.livenowlongevity.com/og-card.jpg

twitter:image

NameCheap, Inc.

LIVENOWLONGEVITY.COM

Abuse

Matheus Fernandez Vieira

Vercel, Inc

Joe Haddad

VERCEL-05

Physician-supervised peptide therapy, weight management, NAD+ IV therapy, and regenerative medicine in Las Vegas, NV.

Las Vegas, Nevada, USA

LiveNow Longevity

Las Vegas

Henderson

Summerlin

Green Valley

Nevada

Physician-supervised peptide therapy, weight management, NAD+ IV therapy, and regenerative medicine in Las Vegas, NV. Led by board-certified neurologist Dr. Charles Kamen, MD.

Albert Einstein College of Medicine

Yale-New Haven Hospital

Loma Linda University

Board-certified neurologist (American Board of Psychiatry and Neurology) and founder of LiveNow Longevity in Las Vegas, Nevada. MD from Albert Einstein College of Medicine (2011), internship at Yale-New Haven Hospital, neurology residency and movement-disorders fellowship at Loma Linda University. Specializes in peptide therapy, GLP-1 weight management, NAD+ IV therapy, regenerative medicine, and personalized longevity protocols.

Physician

Founder & Medical Director, LiveNow Longevity

American Academy of Neurology

Dr. Charles Kamen, MD

Peptide Injection Protocols

Physician-supervised peptide therapy including tissue repair peptides, growth hormone peptides, and melanocortin peptides. Sourced from licensed US 503A/503B compounding pharmacies.

Peptide Therapy

Medical weight management supervised by a board-certified neurologist. Includes GLP-1/GIP medications, comprehensive lab evaluation, and ongoing physician monitoring.

Weight Management

NAD+ intravenous therapy administered by Dr. Charles Kamen, MD at LiveNow Longevity in Las Vegas, NV.

NAD+ IV Therapy

Evidence-based longevity medicine programs including biomarker analysis, hormone optimization, and regenerative protocols supervised by Dr. Charles Kamen, MD.

Longevity Medicine

Regenerative medicine including PRP therapy and growth factor protocols for joint health and tissue repair.

Regenerative Medicine

Intravenous therapy including glutathione, B-complex, vitamin D, magnesium, zinc, and custom IV protocols administered by physician-supervised staff.

IV Therapy

LiveNow Longevity - Physician-Supervised Longevity Medicine Las Vegas

FDA — Pharmacy Compounding Advisory Committee; Notice of Meeting (July 23–24, 2026). Federal Register, published April 16, 2026.

FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1 / 2 / 3 list). Updated May 14, 2026.

FDA — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposes NOT to include semaglutide, tirzepatide, liraglutide). Federal Register, published May 1, 2026.

FDA — Extension of Comment Period for the 503B clinical-need notice (comment period extended to July 30, 2026). Federal Register, published June 26, 2026.

A physician-reviewed, primary-source tracker of the FDA regulatory status of common peptides: 503A compounding categories, the July 2026 PCAC meeting agenda, and the GLP-1 503B proposal.

Peptide Regulatory Status Tracker

LiveNow Longevity (Charles Kamen, MD), Las Vegas

A physician-reviewed reference recording, for each of 25 common peptides, its current U.S. FDA regulatory status: 503A bulk-substance category (1/2/3), whether it is on the July 2026 Pharmacy Compounding Advisory Committee agenda, whether it is an FDA-approved finished drug, and the most recent dated regulatory event — each linked to its primary Federal Register or FDA.gov source. Maintained by LiveNow Longevity, Las Vegas.

Peptide Regulatory Status Tracker (2026)

Peptides by FDA regulatory status

Home

Is BPC-157 FDA-approved or legal to compound in 2026?

What is the FDA doing about peptides in July 2026?

What does "503A Category 1, 2, or 3" mean?

Can compounding pharmacies still make semaglutide or tirzepatide?

Which peptides are actually FDA-approved?

Is this legal advice?

(self.__next_f=self.__next_f||[]).push([0])

self.__next_f.push([1,"1:\"$Sreact.fragment\"\nb:I[68027,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\",1]\n:HL[\"/_next/static/media/e8f2fbee2754df70-s.p.0fzkl03jw-sdz.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:T97b1,"])

self.__next_f.push([1,"0:{\"P\":null,\"c\":[\"\",\"peptide-regulatory-tracker\"],\"q\":\"\",\"i\":false,\"f\":[[[\"\",{\"children\":[\"peptide-regulatory-tracker\",{\"children\":[\"__PAGE__\",{}]}]},\"$undefined\",\"$undefined\",16],[[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"style\",\"0\",{\"nonce\":\"$undefined\",\"precedence\":\"next\",\"href\":\"/_next/static/chunks/0rl9~bep0uw~3.css\",\"children\":\"$2\"}],\"$L3\",\"$L4\",\"$L5\"],\"$L6\"]}],{\"children\":[\"$L7\",{\"children\":[\"$L8\",{},null,false,null]},null,false,\"$@9\"]},null,false,null],\"$La\",false]],\"m\":\"$undefined\",\"G\":[\"$b\",[\"$Lc\"]],\"S\":true,\"h\":null,\"s\":\"$undefined\",\"l\":\"$undefined\",\"p\":\"$undefined\",\"d\":\"$undefined\",\"b\":\"UistBpkBqZrfNp6DalrrV\"}\n"])

self.__next_f.push([1,"d:I[92157,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\ne:I[30824,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\nf:I[39756,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n10:I[37457,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n11:I[48389,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n12:I[52510,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n13:I[79520,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"\"]\n14:I[54887,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n15:I[45280,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n16:I[60473,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"default\"]\n21:I[97367,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"ViewportBoundary\"]\n23:I[97367,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"MetadataBoundary\"]\n24:\"$Sreact.suspense\"\n3:[\"$\",\"script\",\"script-0\",{\"src\":\"/_next/static/chunks/0_ktce.86ahcs.js\",\"async\":true,\"nonce\":\"$undefined\"}]\n4:[\"$\",\"script\",\"script-1\",{\"src\":\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"async\":true,\"nonce\":\"$undefined\"}]\n5:[\"$\",\"script\",\"script-2\",{\"src\":\"/_next/static/chunks/0d3shmwh5_nmn.js\",\"async\":true,\"nonce\":\"$undefined\"}]\n"])

self.__next_f.push([1,"6:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"montserrat_43255d24-module__w968-G__variable open_sans_c900f24c-module__FdTffa__variable\",\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"meta\",null,{\"name\":\"geo.region\",\"content\":\"US-NV\"}],[\"$\",\"meta\",null,{\"name\":\"geo.placename\",\"content\":\"Las Vegas\"}],[\"$\",\"meta\",null,{\"name\":\"geo.position\",\"content\":\"36.007201;-115.115342\"}],[\"$\",\"meta\",null,{\"name\":\"ICBM\",\"content\":\"36.007201, -115.115342\"}],[\"$\",\"meta\",null,{\"name\":\"theme-color\",\"content\":\"#050a07\"}],[\"$\",\"meta\",null,{\"name\":\"mobile-web-app-capable\",\"content\":\"yes\"}],[\"$\",\"meta\",null,{\"name\":\"apple-mobile-web-app-capable\",\"content\":\"yes\"}],[\"$\",\"meta\",null,{\"name\":\"apple-mobile-web-app-status-bar-style\",\"content\":\"black-translucent\"}],[\"$\",\"meta\",null,{\"name\":\"apple-mobile-web-app-title\",\"content\":\"LiveNow Longevity\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/og-card.jpg\"}],[\"$\",\"$Ld\",null,{}],[\"$\",\"noscript\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"\u003cimg height=\\\"1\\\" width=\\\"1\\\" style=\\\"display:none\\\" src=\\\"https://www.facebook.com/tr?id=1364160095508189\u0026ev=PageView\u0026noscript=1\\\" /\u003e\"}}]]}],[\"$\",\"body\",null,{\"children\":[[\"$\",\"$Le\",null,{\"children\":[\"$\",\"main\",null,{\"id\":\"main-content\",\"tabIndex\":-1,\"children\":[[\"$\",\"$Lf\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L10\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L11\",null,{}]]}]}],[\"$\",\"$L12\",null,{}],[\"$\",\"$L13\",null,{\"id\":\"livenow-chat-config\",\"strategy\":\"lazyOnload\",\"children\":\"window.LIVENOW_CHAT_API = 'https://livenow-chatbot.vercel.app';\"}],[\"$\",\"$L13\",null,{\"src\":\"https://livenow-chatbot.vercel.app/widget.js?v=9\",\"strategy\":\"lazyOnload\"}],[\"$\",\"$L14\",null,{\"gaId\":\"G-K065KBPWHF\"}],[\"$\",\"$L15\",null,{}],[\"$\",\"$L16\",null,{}]]}]]}]\n"])

self.__next_f.push([1,"7:[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$Lf\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L10\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]\n17:T3b5f,"])

self.__next_f.push([1,"{\"@context\":\"https://schema.org\",\"@graph\":[{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#webpage\",\"url\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker\",\"name\":\"Peptide Regulatory Status Tracker\",\"description\":\"A physician-reviewed, primary-source tracker of the FDA regulatory status of common peptides: 503A compounding categories, the July 2026 PCAC meeting agenda, and the GLP-1 503B proposal.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https://www.livenowlongevity.com/#website\"},\"about\":{\"@id\":\"https://www.livenowlongevity.com/#business\"},\"reviewedBy\":{\"@id\":\"https://www.livenowlongevity.com/#physician\"},\"lastReviewed\":\"2026-07-01\",\"datePublished\":\"2026-07-01\",\"dateModified\":\"2026-07-01\",\"mainEntity\":{\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#dataset\"},\"breadcrumb\":{\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#breadcrumb\"},\"citation\":[{\"@type\":\"GovernmentService\",\"name\":\"FDA — Pharmacy Compounding Advisory Committee; Notice of Meeting (July 23–24, 2026). Federal Register, published April 16, 2026.\",\"url\":\"https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request\"},{\"@type\":\"GovernmentService\",\"name\":\"FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1 / 2 / 3 list). Updated May 14, 2026.\",\"url\":\"https://www.fda.gov/media/94155/download\"},{\"@type\":\"GovernmentService\",\"name\":\"FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD\u0026C Act (program hub).\",\"url\":\"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act\"},{\"@type\":\"GovernmentService\",\"name\":\"FDA — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposes NOT to include semaglutide, tirzepatide, liraglutide). Federal Register, published May 1, 2026.\",\"url\":\"https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\"},{\"@type\":\"GovernmentService\",\"name\":\"FDA — Extension of Comment Period for the 503B clinical-need notice (comment period extended to July 30, 2026). Federal Register, published June 26, 2026.\",\"url\":\"https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\"},{\"@type\":\"GovernmentService\",\"name\":\"FDA — Human Drug Compounding Laws (conditions for the 503A and 503B exemptions).\",\"url\":\"https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws\"}]},{\"@type\":\"Dataset\",\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#dataset\",\"name\":\"Peptide Regulatory Status Tracker (2026)\",\"description\":\"A physician-reviewed reference recording, for each of 25 common peptides, its current U.S. FDA regulatory status: 503A bulk-substance category (1/2/3), whether it is on the July 2026 Pharmacy Compounding Advisory Committee agenda, whether it is an FDA-approved finished drug, and the most recent dated regulatory event — each linked to its primary Federal Register or FDA.gov source. Maintained by LiveNow Longevity, Las Vegas.\",\"url\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker\",\"creator\":{\"@id\":\"https://www.livenowlongevity.com/#organization\"},\"publisher\":{\"@id\":\"https://www.livenowlongevity.com/#organization\"},\"about\":{\"@id\":\"https://www.livenowlongevity.com/#business\"},\"isAccessibleForFree\":true,\"license\":\"https://creativecommons.org/licenses/by/4.0/\",\"creditText\":\"LiveNow Longevity (Charles Kamen, MD), Las Vegas\",\"datePublished\":\"2026-07-01\",\"dateModified\":\"2026-07-01\",\"distribution\":[{\"@type\":\"DataDownload\",\"encodingFormat\":\"text/csv\",\"contentUrl\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker\"},{\"@type\":\"DataDownload\",\"encodingFormat\":\"application/json\",\"contentUrl\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker\"}],\"keywords\":[\"peptide FDA status\",\"503A bulks list\",\"PCAC July 2026\",\"BPC-157 FDA\",\"GLP-1 503B\",\"peptide compounding regulation\"],\"variableMeasured\":[\"Substance name\",\"FDA-approved drug (yes/no)\",\"503A regulatory status\",\"PCAC July 2026 agenda day\",\"Most recent regulatory event\",\"Primary source citation\"]},{\"@type\":\"ItemList\",\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#itemlist\",\"name\":\"Peptides by FDA regulatory status\",\"numberOfItems\":24,\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"BPC-157\",\"description\":\"BPC-157: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Scheduled for FDA advisory-committee review as a bulk substance nominated for inclusion on the 503A list.\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"KPV\",\"description\":\"KPV: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Nominated for the 503A list and scheduled for advisory-committee review.\"}},{\"@type\":\"ListItem\",\"position\":3,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"TB-500\",\"description\":\"TB-500: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Nominated for the 503A list and scheduled for advisory-committee review.\"}},{\"@type\":\"ListItem\",\"position\":4,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"MOTS-c\",\"description\":\"MOTS-c: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Nominated for the 503A list and scheduled for advisory-committee review.\"}},{\"@type\":\"ListItem\",\"position\":5,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Emideltide\",\"description\":\"Emideltide: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Nominated for the 503A list and scheduled for advisory-committee review.\"}},{\"@type\":\"ListItem\",\"position\":6,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Semax\",\"description\":\"Semax: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Nominated for the 503A list and scheduled for advisory-committee review.\"}},{\"@type\":\"ListItem\",\"position\":7,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Epitalon\",\"description\":\"Epitalon: Under PCAC review. Not FDA-approved and not currently on the 503A bulks list. Nominated for the 503A list and scheduled for advisory-committee review.\"}},{\"@type\":\"ListItem\",\"position\":8,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"GHK-Cu (topical / non-injectable)\",\"description\":\"GHK-Cu (topical / non-injectable): 503A Category 1. Non-injectable GHK-Cu is on Category 1 (under evaluation; may be used in compounding while FDA completes its review). The injectable route is NOT — see the injectable row.\"}},{\"@type\":\"ListItem\",\"position\":9,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"GHK-Cu (injectable)\",\"description\":\"GHK-Cu (injectable): Not on the 503A list. The injectable route of GHK-Cu is not on any 503A category list; its nomination was withdrawn and not reinstated. Not FDA-approved.\"}},{\"@type\":\"ListItem\",\"position\":10,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Vasoactive intestinal peptide\",\"description\":\"Vasoactive intestinal peptide: 503A Category 1. On Category 1 (under evaluation; may be used in compounding while FDA completes its review). Not FDA-approved as a finished drug.\"}},{\"@type\":\"ListItem\",\"position\":11,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Kisspeptin-10\",\"description\":\"Kisspeptin-10: 503A Category 2. On Category 2 — FDA identified a significant safety risk, so it should not be used in 503A compounding. Not FDA-approved.\"}},{\"@type\":\"ListItem\",\"position\":12,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Ibutamoren\",\"description\":\"Ibutamoren: 503A Category 2. On Category 2 — FDA identified a significant safety risk, so it should not be used in 503A compounding. Not FDA-approved. (Chemically a small molecule, not a peptide, but frequently sold under the \\\"peptide\\\" umbrella.)\"}},{\"@type\":\"ListItem\",\"position\":13,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Cibinetide\",\"description\":\"Cibinetide: 503A Category 3. On Category 3 — nominated without adequate supporting information for FDA to evaluate. Not FDA-approved.\"}},{\"@type\":\"ListItem\",\"position\":14,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"CJC-1295\",\"description\":\"CJC-1295: Not on the 503A list. Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn.\"}},{\"@type\":\"ListItem\",\"position\":15,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Ipamorelin\",\"description\":\"Ipamorelin: Not on the 503A list. Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn.\"}},{\"@type\":\"ListItem\",\"position\":16,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Thymosin alpha-1\",\"description\":\"Thymosin alpha-1: Not on the 503A list. Not on any current 503A category list and not FDA-approved in the U.S. (approved in some other countries). Its U.S. nomination for the 503A bulks list was withdrawn.\"}},{\"@type\":\"ListItem\",\"position\":17,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Selank\",\"description\":\"Selank: Not on the 503A list. Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn.\"}},{\"@type\":\"ListItem\",\"position\":18,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"AOD-9604\",\"description\":\"AOD-9604: Not on the 503A list. Not on any current 503A category list and not FDA-approved. Its nomination for the 503A bulks list was withdrawn.\"}},{\"@type\":\"ListItem\",\"position\":19,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Sermorelin\",\"description\":\"Sermorelin: Not on the 503A list. A sermorelin finished drug (Geref) was historically FDA-approved but the brand is discontinued; sermorelin is not on any current 503A category list. Its compounding eligibility rests on prior-approval history and is not settled here.\"}},{\"@type\":\"ListItem\",\"position\":20,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Semaglutide\",\"description\":\"Semaglutide: FDA-approved drug. FDA-approved as branded finished drugs. Separately, FDA has proposed NOT to add semaglutide to the 503B outsourcing-facility bulks list; the comment period on that notice runs through July 30, 2026. Shortage-based compounding has ended.\"}},{\"@type\":\"ListItem\",\"position\":21,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Tirzepatide\",\"description\":\"Tirzepatide: FDA-approved drug. FDA-approved as branded finished drugs. Separately, FDA has proposed NOT to add tirzepatide to the 503B outsourcing-facility bulks list; the comment period on that notice runs through July 30, 2026. Shortage-based compounding has ended.\"}},{\"@type\":\"ListItem\",\"position\":22,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Liraglutide\",\"description\":\"Liraglutide: FDA-approved drug. FDA-approved as branded finished drugs. Separately, FDA has proposed NOT to add liraglutide to the 503B outsourcing-facility bulks list; the comment period on that notice runs through July 30, 2026.\"}},{\"@type\":\"ListItem\",\"position\":23,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Tesamorelin\",\"description\":\"Tesamorelin: FDA-approved drug. FDA-approved as a finished drug (Egrifta), a growth-hormone-releasing-hormone analog. This is an approved product, distinct from the compounding lists above.\"}},{\"@type\":\"ListItem\",\"position\":24,\"item\":{\"@type\":\"MedicalEntity\",\"name\":\"Bremelanotide\",\"description\":\"Bremelanotide: FDA-approved drug. The finished drug Vyleesi is FDA-approved. Compounded \\\"PT-141\\\" is not the approved product and is not FDA-approved.\"}}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.livenowlongevity.com\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peptide Regulatory Status Tracker\",\"item\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker\"}]},{\"@type\":\"FAQPage\",\"@id\":\"https://www.livenowlongevity.com/peptide-regulatory-tracker#faq\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Is BPC-157 FDA-approved or legal to compound in 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. As of the FDA 503A category list updated May 14, 2026, BPC-157 is not FDA-approved and is not on the 503A bulks list. It is scheduled for review by the FDA Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026, as a substance nominated for possible inclusion on that list. Being on a meeting agenda is not approval and does not make a substance compoundable.\"}},{\"@type\":\"Question\",\"name\":\"What is the FDA doing about peptides in July 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The FDA Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to discuss whether several nominated peptides should be added to the 503A bulks list. July 23 covers BPC-157, KPV, TB-500, and MOTS-c; July 24 covers emideltide (DSIP), semax, and epitalon. The committee's recommendation is non-binding — FDA still has to complete formal rulemaking afterward. The public docket is FDA-2025-N-6895.\"}},{\"@type\":\"Question\",\"name\":\"What does \\\"503A Category 1, 2, or 3\\\" mean?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"These are the FDA's working categories for bulk substances nominated for use in pharmacy compounding under section 503A. Category 1 means \\\"under evaluation\\\" — a substance may generally be used in compounding while FDA finishes its review. Category 2 means FDA identified a significant safety risk, so it should not be compounded. Category 3 means the nomination lacked adequate supporting information. A substance on none of these lists was either never nominated or had its nomination withdrawn.\"}},{\"@type\":\"Question\",\"name\":\"Can compounding pharmacies still make semaglutide or tirzepatide?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Generally no. Compounding of the GLP-1 drugs was permitted only while they were on the FDA drug-shortage list; those shortages resolved, ending that basis. Separately, in a Federal Register notice published May 1, 2026 (docket FDA-2018-N-3240), FDA proposed NOT to add semaglutide, tirzepatide, or liraglutide to the 503B outsourcing-facility bulks list. The comment period on that notice was extended to July 30, 2026.\"}},{\"@type\":\"Question\",\"name\":\"Which peptides are actually FDA-approved?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Only a handful of peptide DRUGS are FDA-approved as finished products, and that is a completely different pathway from the compounding lists. Approved examples include semaglutide, tirzepatide, and liraglutide (GLP-1 drugs), tesamorelin (Egrifta), and bremelanotide (Vyleesi). Most peptides marketed by wellness brands — BPC-157, CJC-1295, ipamorelin, and so on — are not FDA-approved.\"}},{\"@type\":\"Question\",\"name\":\"Is this legal advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This tracker reports the regulatory status of peptides as recorded in public FDA and Federal Register documents. It is educational information, not medical or legal advice, and the underlying FDA lists change. Verify the current status against the linked primary source before relying on it, and consult a licensed professional for your situation.\"}}]}]}"])

self.__next_f.push([1,"8:[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$17\"}}],\"$L18\",\"$L19\",\"$L1a\",\"$L1b\",\"$L1c\"],[\"$L1d\",\"$L1e\"],\"$L1f\"]}]\n20:[]\n9:\"$W20\"\na:[\"$\",\"$1\",\"h\",{\"children\":[null,[\"$\",\"$L21\",null,{\"children\":\"$L22\"}],[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$L23\",null,{\"children\":[\"$\",\"$24\",null,{\"name\":\"Next.Metadata\",\"children\":\"$L25\"}]}]}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]]}]\n26:T97b1,"])

self.__next_f.push([1,"c:[\"$\",\"style\",\"0\",{\"nonce\":\"$undefined\",\"precedence\":\"next\",\"href\":\"/_next/static/chunks/0rl9~bep0uw~3.css\",\"children\":\"$26\"}]\n"])

self.__next_f.push([1,"27:I[45678,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\",\"/_next/static/chunks/0.00sa.2gr0nb.js\"],\"default\"]\n28:I[30107,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\",\"/_next/static/chunks/0.00sa.2gr0nb.js\"],\"default\"]\n29:I[22016,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\",\"/_next/static/chunks/0.00sa.2gr0nb.js\"],\"\"]\n2a:I[70222,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\",\"/_next/static/chunks/0.00sa.2gr0nb.js\"],\"default\"]\n38:I[97367,[\"/_next/static/chunks/0_ktce.86ahcs.js\",\"/_next/static/chunks/08.l1x9-r0a9s.js\",\"/_next/static/chunks/0d3shmwh5_nmn.js\"],\"OutletBoundary\"]\n18:[\"$\",\"$L27\",null,{}]\n19:[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__rail\",\"aria-hidden\":\"true\"}]\n"])

self.__next_f.push([1,"1a:[\"$\",\"main\",null,{\"children\":[[\"$\",\"section\",null,{\"className\":\"Interior-module__Xz7aSq__hero\",\"children\":[[\"$\",\"$L28\",null,{\"className\":\"Interior-module__Xz7aSq__heroCanvas\",\"variant\":\"interior\"}],[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__heroBg\"}],[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__heroContent\",\"children\":[[\"$\",\"span\",null,{\"className\":\"Interior-module__Xz7aSq__eyebrow Award-module__9Djg4W__eyebrow\",\"children\":[\"Original reference · reviewed \",\"July 1, 2026\"]}],[\"$\",\"h1\",null,{\"children\":\"Peptide Regulatory Status Tracker\"}],[\"$\",\"p\",null,{\"children\":[\"Where \",24,\" peptides actually stand with the U.S. FDA — the 503A compounding categories, the \",7,\" substances on the \",[\"$\",\"strong\",null,{\"children\":\"July 23–24, 2026\"}],\" advisory-committee agenda, and the GLP-1 503B proposal. Every row links to its primary Federal Register or FDA.gov source. Filter it, search it, and download the data.\"]}]]}]]}],[\"$\",\"section\",null,{\"className\":\"section Interior-module__Xz7aSq__intro\",\"children\":[\"$\",\"div\",null,{\"className\":\"text-container\",\"children\":[[\"$\",\"p\",null,{\"className\":\"Interior-module__Xz7aSq__introText\",\"children\":[\"“Is this peptide FDA-approved? Is it legal to compound?” is one of the hardest questions to answer honestly, because the rules are changing month to month and most of what circulates online is either a retailer’s sales copy or a law firm’s prose. This tracker does one thing: it records the\",\" \",[\"$\",\"strong\",null,{\"children\":\"current regulatory status\"}],\" of each peptide from primary U.S. government documents, with the source linked on every row.\"]}],[\"$\",\"p\",null,{\"className\":\"Interior-module__Xz7aSq__introText\",\"children\":[\"The conservative spine matters. \",[\"$\",\"strong\",null,{\"children\":\"Being on the 503A list is not the same as FDA approval.\"}],\" \",\"Only \",5,\"of the substances below are FDA-approved finished drugs. Most of the “wellness” peptides — BPC-157, CJC-1295, ipamorelin — are on \",[\"$\",\"em\",null,{\"children\":\"no\"}],\" current 503A list at all; their nominations were withdrawn. And a spot on the July 2026 advisory-committee agenda is a review, not an approval. For the underlying biochemistry, see \",[\"$\",\"$L29\",null,{\"href\":\"/is-it-a-peptide\",\"children\":\"Is It a Peptide?\"}],\"; for the deeper compounding-law explainer, see \",[\"$\",\"$L29\",null,{\"href\":\"/fda-peptide-compounding-status\",\"children\":\"FDA peptide compounding status\"}],\".\"]}]]}]}],[\"$\",\"section\",null,{\"className\":\"ReferencePage-module__8GRLWW__dataSection\",\"children\":[\"$\",\"div\",null,{\"className\":\"ReferencePage-module__8GRLWW__panel\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"ReferencePage-module__8GRLWW__sectionTitle\",\"children\":\"The Tracker\"}],[\"$\",\"p\",null,{\"className\":\"ReferencePage-module__8GRLWW__sectionLead\",\"children\":[\"Filter by status, search any peptide or brand, and export the full dataset as CSV or JSON (CC BY 4.0 — free to reuse with attribution). Status reflects the FDA 503A category list updated\",\" \",\"May 14, 2026\",\" and Federal Register notices verified \",\"July 1, 2026\",\".\"]}],[\"$\",\"$L2a\",null,{}],[\"$\",\"p\",null,{\"className\":\"ReferencePage-module__8GRLWW__note\",\"style\":{\"marginTop\":\"1.25rem\"},\"children\":[[\"$\",\"strong\",null,{\"children\":\"How this is built:\"}],\"Rows marked as primary were read directly from the Federal Register full text (PCAC meeting notice, docket FDA-2025-N-6895; and the 503B clinical-need notice, docket FDA-2018-N-3240) and the FDA 503A category list PDF. Rows marked “reported” rest on secondary reporting and are labeled as such. FDA lists change — always confirm against the linked source at time of use.\"]}],[\"$\",\"p\",null,{\"className\":\"ReferencePage-module__8GRLWW__disclaimer\",\"children\":\"Scope \u0026 compliance: This is regulatory-status information, not medical or legal advice. It contains no doses and makes no efficacy claims. Nothing here should be read as encouragement to use any unapproved substance.\"}]]}]}],\"$L2b\",\"$L2c\",\"$L2d\"]}]\n"])

self.__next_f.push([1,"1b:[\"$\",\"section\",null,{\"className\":\"Interior-module__Xz7aSq__cta\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"Interior-module__Xz7aSq__ctaTitle\",\"children\":\"Ready to start your longevity care?\"}],[\"$\",\"p\",null,{\"className\":\"Interior-module__Xz7aSq__ctaSub\",\"children\":\"Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.\"}],[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__ctaBtnRow\",\"children\":[\"$\",\"a\",null,{\"href\":\"/book\",\"className\":\"Interior-module__Xz7aSq__pillBtn Award-module__9Djg4W__pillBtn\",\"children\":\"Book Your $88 Evaluation\"}]}],[\"$\",\"p\",null,{\"className\":\"Interior-module__Xz7aSq__ctaPhoneRow\",\"children\":[\"Prefer to talk?\",\" \",[\"$\",\"a\",null,{\"href\":\"tel:+17028082650\",\"children\":\"Call (702) 808-2650\"}],\" or\",\" \",[\"$\",\"a\",null,{\"href\":\"sms:+17028082650?\u0026body=Hi%2C%20I%27d%20like%20to%20book%20the%20%2488%20evaluation.\",\"children\":\"text us\"}],\" \",\"to book.\"]}],[\"$\",\"div\",null,{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/peptide-clinic-las-vegas\",\"className\":\"Interior-module__Xz7aSq__ctaClinicLink\",\"children\":[\"Physician-led peptide therapy in Las Vegas. Visit our clinic\",[\"$\",\"svg\",null,{\"width\":\"16\",\"height\":\"16\",\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":\"2\",\"children\":[\"$\",\"path\",null,{\"d\":\"M5 12h14M12 5l7 7-7 7\",\"strokeLinecap\":\"round\",\"strokeLinejoin\":\"round\"}]}]]}]}],[\"$\",\"p\",null,{\"className\":\"Interior-module__Xz7aSq__ctaPhoneRow\",\"children\":[\"Also serving \",[\"$\",\"$L29\",null,{\"href\":\"/peptide-clinic-henderson\",\"children\":\"Henderson\"}],\" — or explore\",\" \",[\"$\",\"$L29\",null,{\"href\":\"/semaglutide-las-vegas\",\"children\":\"semaglutide weight loss in Las Vegas\"}],\".\"]}]]}]\n"])

self.__next_f.push([1,"1c:[\"$\",\"footer\",null,{\"id\":\"contact\",\"className\":\"Footer-module__S6Hkya__footer\",\"children\":[\"$\",\"div\",null,{\"className\":\"Footer-module__S6Hkya__inner\",\"children\":[[\"$\",\"div\",null,{\"className\":\"Footer-module__S6Hkya__top\",\"children\":[[\"$\",\"div\",null,{\"className\":\"Footer-module__S6Hkya__brand\",\"children\":[[\"$\",\"span\",null,{\"className\":\"Footer-module__S6Hkya__brandAccent\",\"children\":\"Live\"}],\"Now Longevity\",[\"$\",\"p\",null,{\"className\":\"Footer-module__S6Hkya__tagline\",\"children\":\"Physician-supervised longevity therapy in Las Vegas.\"}],[\"$\",\"div\",null,{\"className\":\"Footer-module__S6Hkya__contact\",\"children\":[[\"$\",\"a\",null,{\"href\":\"tel:702-808-2650\",\"className\":\"Footer-module__S6Hkya__contactItem\",\"children\":\"702-808-2650\"}],[\"$\",\"a\",null,{\"href\":\"mailto:info@livenowlongevity.com\",\"className\":\"Footer-module__S6Hkya__contactItem\",\"children\":\"info@livenowlongevity.com\"}],[\"$\",\"p\",null,{\"className\":\"Footer-module__S6Hkya__address\",\"children\":[\"9975 S Eastern Ave Ste 130\",[\"$\",\"br\",null,{}],\"Las Vegas, NV 89183\"]}],[\"$\",\"a\",null,{\"href\":\"https://www.instagram.com/livenow_longevity\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"Footer-module__S6Hkya__social\",\"aria-label\":\"@livenow_longevity on Instagram\",\"children\":[[\"$\",\"svg\",null,{\"width\":\"20\",\"height\":\"20\",\"viewBox\":\"0 0 24 24\",\"fill\":\"none\",\"stroke\":\"currentColor\",\"strokeWidth\":\"2\",\"children\":[[\"$\",\"rect\",null,{\"x\":\"2\",\"y\":\"2\",\"width\":\"20\",\"height\":\"20\",\"rx\":\"5\",\"ry\":\"5\"}],[\"$\",\"path\",null,{\"d\":\"M16 11.37A4 4 0 1 1 12.63 8 4 4 0 0 1 16 11.37z\"}],[\"$\",\"line\",null,{\"x1\":\"17.5\",\"y1\":\"6.5\",\"x2\":\"17.51\",\"y2\":\"6.5\"}]]}],[\"$\",\"span\",null,{\"children\":\"@livenow_longevity\"}]]}],[\"$\",\"a\",null,{\"href\":\"https://peptideclinicfinder.com/clinics/livenow-longevity-las-vegas\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"className\":\"Footer-module__S6Hkya__featuredBadge\",\"aria-label\":\"Featured on Peptide Clinic Finder\",\"children\":[\"$\",\"img\",null,{\"src\":\"https://peptideclinicfinder.com/featured-badge.svg\",\"alt\":\"Featured on Peptide Clinic Finder\",\"width\":300,\"height\":64,\"loading\":\"lazy\"}]}]]}]]}],[[\"$\",\"nav\",\"Clinic Locations\",{\"className\":\"Footer-module__S6Hkya__subCol\",\"aria-label\":\"Clinic Locations\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"Footer-module__S6Hkya__subColTitle\",\"children\":\"Clinic Locations\"}],[\"$\",\"ul\",null,{\"className\":\"Footer-module__S6Hkya__subColList\",\"children\":[[\"$\",\"li\",\"Las Vegas Peptide Clinic\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/peptide-clinic-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Las Vegas Peptide Clinic\"}]}],[\"$\",\"li\",\"Henderson Peptide Clinic\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/peptide-clinic-henderson\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Henderson Peptide Clinic\"}]}],[\"$\",\"li\",\"Longevity \u0026 Anti-Aging Clinic Las Vegas\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/anti-aging-clinic-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Longevity \u0026 Anti-Aging Clinic Las Vegas\"}]}]]}]]}],[\"$\",\"nav\",\"Medical Services\",{\"className\":\"Footer-module__S6Hkya__subCol\",\"aria-label\":\"Medical Services\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"Footer-module__S6Hkya__subColTitle\",\"children\":\"Medical Services\"}],[\"$\",\"ul\",null,{\"className\":\"Footer-module__S6Hkya__subColList\",\"children\":[[\"$\",\"li\",\"Peptide Therapy\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/services/peptide-therapy\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Peptide Therapy\"}]}],[\"$\",\"li\",\"Anti-Aging Peptides\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/anti-aging-peptides\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Anti-Aging Peptides\"}]}],[\"$\",\"li\",\"NAD+ for Anti-Aging\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/nad-anti-aging\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"NAD+ for Anti-Aging\"}]}],[\"$\",\"li\",\"Medical Weight Loss Las Vegas\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/medical-weight-loss-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Medical Weight Loss Las Vegas\"}]}],[\"$\",\"li\",\"GLP-1 Weight Loss Las Vegas\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/glp-1-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"GLP-1 Weight Loss Las Vegas\"}]}],[\"$\",\"li\",\"Semaglutide Las Vegas\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/semaglutide-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Semaglutide Las Vegas\"}]}],\"$L2e\",\"$L2f\",\"$L30\",\"$L31\",\"$L32\",\"$L33\",\"$L34\"]}]]}],\"$L35\"]]}],\"$L36\"]}]}]\n"])

self.__next_f.push([1,".Navbar-module__cJzEcG__navbar{z-index:100;background:var(--bg-dark);padding:1.1rem 5%;transition:background .4s,-webkit-backdrop-filter .4s,backdrop-filter .4s,box-shadow .4s,p

self.__next_f.push([1,"1d:[\"$\",\"style\",\"0\",{\"nonce\":\"$undefined\",\"precedence\":\"next\",\"href\":\"/_next/static/chunks/0m~mqarj0j45e.css\",\"children\":\"$37\"}]\n1e:[\"$\",\"script\",\"script-0\",{\"src\":\"/_next/static/chunks/0.00sa.2gr0nb.js\",\"async\":true,\"nonce\":\"$undefined\"}]\n1f:[\"$\",\"$L38\",null,{\"children\":[\"$\",\"$24\",null,{\"name\":\"Next.MetadataOutlet\",\"children\":\"$@39\"}]}]\n"])

self.__next_f.push([1,"2b:[\"$\",\"section\",null,{\"className\":\"Interior-module__Xz7aSq__intro\",\"children\":[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__introText\",\"children\":[[\"$\",\"h2\",null,{\"children\":\"What’s Happening July 23–24, 2026\"}],[\"$\",\"p\",null,{\"children\":[\"The FDA Pharmacy Compounding Advisory Committee (PCAC) meets over two days to consider peptides nominated for the 503A bulks list. On \",[\"$\",\"strong\",null,{\"children\":\"July 23\"}],\" the committee discusses BPC-157, KPV, TB-500, and MOTS-c; on \",[\"$\",\"strong\",null,{\"children\":\"July 24\"}],\" it discusses emideltide (delta sleep-inducing peptide), semax, and epitalon. The committee reviews the specific use each was nominated for, hears from nominators, and votes a\",\" \",[\"$\",\"em\",null,{\"children\":\"recommendation\"}],\" — which is non-binding. FDA still has to complete formal rulemaking before anything changes. The public docket is FDA-2025-N-6895.\"]}]]}]}]\n"])

self.__next_f.push([1,"2c:[\"$\",\"section\",null,{\"className\":\"Interior-module__Xz7aSq__intro\",\"children\":[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__introText\",\"children\":[[\"$\",\"h2\",null,{\"children\":\"Frequently Asked Questions\"}],[[\"$\",\"details\",\"Is BPC-157 FDA-approved or legal to compound in 2026?\",{\"style\":{\"borderTop\":\"1px solid #e3ece6\",\"padding\":\"1rem 0\"},\"children\":[[\"$\",\"summary\",null,{\"style\":{\"cursor\":\"pointer\",\"fontWeight\":600,\"color\":\"#163026\",\"fontSize\":\"1.02rem\"},\"children\":\"Is BPC-157 FDA-approved or legal to compound in 2026?\"}],[\"$\",\"p\",null,{\"style\":{\"marginTop\":\"0.6rem\",\"color\":\"#3a4a42\",\"lineHeight\":1.6},\"children\":\"No. As of the FDA 503A category list updated May 14, 2026, BPC-157 is not FDA-approved and is not on the 503A bulks list. It is scheduled for review by the FDA Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026, as a substance nominated for possible inclusion on that list. Being on a meeting agenda is not approval and does not make a substance compoundable.\"}]]}],[\"$\",\"details\",\"What is the FDA doing about peptides in July 2026?\",{\"style\":{\"borderTop\":\"1px solid #e3ece6\",\"padding\":\"1rem 0\"},\"children\":[[\"$\",\"summary\",null,{\"style\":{\"cursor\":\"pointer\",\"fontWeight\":600,\"color\":\"#163026\",\"fontSize\":\"1.02rem\"},\"children\":\"What is the FDA doing about peptides in July 2026?\"}],[\"$\",\"p\",null,{\"style\":{\"marginTop\":\"0.6rem\",\"color\":\"#3a4a42\",\"lineHeight\":1.6},\"children\":\"The FDA Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to discuss whether several nominated peptides should be added to the 503A bulks list. July 23 covers BPC-157, KPV, TB-500, and MOTS-c; July 24 covers emideltide (DSIP), semax, and epitalon. The committee's recommendation is non-binding — FDA still has to complete formal rulemaking afterward. The public docket is FDA-2025-N-6895.\"}]]}],[\"$\",\"details\",\"What does \\\"503A Category 1, 2, or 3\\\" mean?\",{\"style\":{\"borderTop\":\"1px solid #e3ece6\",\"padding\":\"1rem 0\"},\"children\":[[\"$\",\"summary\",null,{\"style\":{\"cursor\":\"pointer\",\"fontWeight\":600,\"color\":\"#163026\",\"fontSize\":\"1.02rem\"},\"children\":\"What does \\\"503A Category 1, 2, or 3\\\" mean?\"}],[\"$\",\"p\",null,{\"style\":{\"marginTop\":\"0.6rem\",\"color\":\"#3a4a42\",\"lineHeight\":1.6},\"children\":\"These are the FDA's working categories for bulk substances nominated for use in pharmacy compounding under section 503A. Category 1 means \\\"under evaluation\\\" — a substance may generally be used in compounding while FDA finishes its review. Category 2 means FDA identified a significant safety risk, so it should not be compounded. Category 3 means the nomination lacked adequate supporting information. A substance on none of these lists was either never nominated or had its nomination withdrawn.\"}]]}],[\"$\",\"details\",\"Can compounding pharmacies still make semaglutide or tirzepatide?\",{\"style\":{\"borderTop\":\"1px solid #e3ece6\",\"padding\":\"1rem 0\"},\"children\":[[\"$\",\"summary\",null,{\"style\":{\"cursor\":\"pointer\",\"fontWeight\":600,\"color\":\"#163026\",\"fontSize\":\"1.02rem\"},\"children\":\"Can compounding pharmacies still make semaglutide or tirzepatide?\"}],[\"$\",\"p\",null,{\"style\":{\"marginTop\":\"0.6rem\",\"color\":\"#3a4a42\",\"lineHeight\":1.6},\"children\":\"Generally no. Compounding of the GLP-1 drugs was permitted only while they were on the FDA drug-shortage list; those shortages resolved, ending that basis. Separately, in a Federal Register notice published May 1, 2026 (docket FDA-2018-N-3240), FDA proposed NOT to add semaglutide, tirzepatide, or liraglutide to the 503B outsourcing-facility bulks list. The comment period on that notice was extended to July 30, 2026.\"}]]}],[\"$\",\"details\",\"Which peptides are actually FDA-approved?\",{\"style\":{\"borderTop\":\"1px solid #e3ece6\",\"padding\":\"1rem 0\"},\"children\":[[\"$\",\"summary\",null,{\"style\":{\"cursor\":\"pointer\",\"fontWeight\":600,\"color\":\"#163026\",\"fontSize\":\"1.02rem\"},\"children\":\"Which peptides are actually FDA-approved?\"}],\"$L3a\"]}],\"$L3b\"]]}]}]\n"])

self.__next_f.push([1,"2d:[\"$\",\"section\",null,{\"className\":\"Interior-module__Xz7aSq__intro\",\"children\":[\"$\",\"div\",null,{\"className\":\"Interior-module__Xz7aSq__introText\",\"children\":[[\"$\",\"h2\",null,{\"children\":\"Primary Sources\"}],[\"$\",\"ul\",null,{\"style\":{\"marginTop\":\"0.75rem\",\"lineHeight\":1.7,\"color\":\"#3a4a42\",\"fontSize\":\"0.9rem\"},\"children\":[[\"$\",\"li\",\"https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request\",{\"style\":{\"marginBottom\":\"0.6rem\"},\"children\":[[\"$\",\"a\",null,{\"href\":\"https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"style\":{\"color\":\"#1f7a4d\"},\"children\":\"FDA — Pharmacy Compounding Advisory Committee; Notice of Meeting (July 23–24, 2026). Federal Register, published April 16, 2026.\"}],\" — Docket FDA-2025-N-6895.\"]}],[\"$\",\"li\",\"https://www.fda.gov/media/94155/download\",{\"style\":{\"marginBottom\":\"0.6rem\"},\"children\":[[\"$\",\"a\",null,{\"href\":\"https://www.fda.gov/media/94155/download\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"style\":{\"color\":\"#1f7a4d\"},\"children\":\"FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1 / 2 / 3 list). Updated May 14, 2026.\"}],\"\"]}],[\"$\",\"li\",\"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act\",{\"style\":{\"marginBottom\":\"0.6rem\"},\"children\":[[\"$\",\"a\",null,{\"href\":\"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"style\":{\"color\":\"#1f7a4d\"},\"children\":\"FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD\u0026C Act (program hub).\"}],\"\"]}],[\"$\",\"li\",\"https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\",{\"style\":{\"marginBottom\":\"0.6rem\"},\"children\":[[\"$\",\"a\",null,{\"href\":\"https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"style\":{\"color\":\"#1f7a4d\"},\"children\":\"FDA — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (proposes NOT to include semaglutide, tirzepatide, liraglutide). Federal Register, published May 1, 2026.\"}],\" — Docket FDA-2018-N-3240.\"]}],[\"$\",\"li\",\"https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\",{\"style\":{\"marginBottom\":\"0.6rem\"},\"children\":[[\"$\",\"a\",null,{\"href\":\"https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"style\":{\"color\":\"#1f7a4d\"},\"children\":\"FDA — Extension of Comment Period for the 503B clinical-need notice (comment period extended to July 30, 2026). Federal Register, published June 26, 2026.\"}],\" — Docket FDA-2018-N-3240.\"]}],[\"$\",\"li\",\"https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws\",{\"style\":{\"marginBottom\":\"0.6rem\"},\"children\":[[\"$\",\"a\",null,{\"href\":\"https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws\",\"target\":\"_blank\",\"rel\":\"noopener noreferrer\",\"style\":{\"color\":\"#1f7a4d\"},\"children\":\"FDA — Human Drug Compounding Laws (conditions for the 503A and 503B exemptions).\"}],\"\"]}]]}],[\"$\",\"p\",null,{\"style\":{\"fontSize\":\"0.8rem\",\"color\":\"#5a6b62\",\"marginTop\":\"1rem\"},\"children\":\"Reviewed by Dr. Charles Kamen, MD — LiveNow Longevity, Las Vegas. This reference is educational and is not medical or legal advice.\"}]]}]}]\n"])

self.__next_f.push([1,"2e:[\"$\",\"li\",\"Tirzepatide Las Vegas\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/tirzepatide-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Tirzepatide Las Vegas\"}]}]\n2f:[\"$\",\"li\",\"TRT Las Vegas\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/trt-las-vegas\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"TRT Las Vegas\"}]}]\n30:[\"$\",\"li\",\"Weight Management\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/services/weight-management\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Weight Management\"}]}]\n31:[\"$\",\"li\",\"Regenerative Medicine\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/services/regenerative-medicine\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Regenerative Medicine\"}]}]\n32:[\"$\",\"li\",\"NAD+ Therapy\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/services/nad-therapy\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"NAD+ Therapy\"}]}]\n33:[\"$\",\"li\",\"Hormone Therapy\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/services/hormone-therapy\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Hormone Therapy\"}]}]\n34:[\"$\",\"li\",\"Longevity Medicine\",{\"children\":[\"$\",\"$L29\",null,{\"href\":\"/services/longevity-medicine\",\"className\":\"Footer-module__S6Hkya__navLink\",\"children\":\"Longevity Medicine\"}]}]\n"])

Requests	IP Address	Location	AS Autonomous System
63	76.76.21.164	Walnut, California, United States	AS16509Amazon.com, Inc.
63	1	-	-

Security Scan Report: www.livenowlongevity.com

Summary

AI Security Verdict

Low Risk

Safety Factors

Details

Screenshot

Page Load Overview

Language Analysis

Primary Language

Detection Details

Website Classification

Primary Category

All Detected Categories

Detected Features

Domain & IP Information

Page Statistics

Detected Technologies2

Content Similarity HashesFor malware variant detection

TLSH (Trend Micro Locality Sensitive Hash)

ssdeep (Context Triggered Piecewise Hashing)

sdhash (Similarity Digest Hashing)

Image Hashes

Perceptual Hashes

Other Hashes

Scan History